Kinoshita J, Haga S, Shimizu T, Imamura H, Watanabe O, Kajiwara T
Department of Surgery, Tokyo Women's Medical College Daini Hospital, Japan.
Breast Cancer Res Treat. 1999 Jan;53(2):177-83. doi: 10.1023/a:1006130601575.
The purpose of this prospective study was to evaluate the expression of CD44 splice variant epitopes in human breast cancer and their potential as prognostic indicators. Invasive breast cancer tissues obtained from 91 patients were examined for expression of the standard CD44 antigen and variant CD44 antigens (v5, v6, v7, v7-v8, and v8-v10) by immunohistochemical staining to investigate the relations of these antigens to clinicopathological factors and prognosis. The expression of standard CD44 antigen was detected in 54.9% of 91 patients with primary human breast cancer. The variant epitopes of CD44 examined, i.e., v5, v6, v7, v7-v8, and v8-v10, were expressed in 54.9%, 54.9%, 0%, 34.1%, and 0%, respectively. There was a significant difference in tumor size, lymph nodal status, and degree of lymphatic permeation between patients who were positive for exon v7-v8 and those negative for this variant (p < 0.01). Prognosis was also significantly worse in patients positive for CD44 v7-v8 than in those negative for this variant. However, multivariate analysis with the three prognostic indicators tumor size, lymph nodal status, and the degree of lymphatic invasion, has shown that the expression of CD44 v7-v8 antigen in breast carcinoma was not a significant independent prognostic factor and was closely dependent on lymphatic invasion and nodal status. Fourteen of 31 patients who were positive for CD44 v7-v8 experienced recurrences. The mode of recurrence was lymphatic metastasis in 10 out of these 14 patients. Breast cancer cells expressing v7-v8 CD44 antigen have an extremely high affinity for lymph nodes and lymphatic vessels, and are likely to metastasize to distant lymph nodes even at a very early stage in the progression of this disease. This suggests that not only the anatomical factors but also organ affinity plays an important role in the establishment of lymph nodal metastasis of breast cancer.
本前瞻性研究的目的是评估CD44剪接变异体表位在人类乳腺癌中的表达及其作为预后指标的潜力。通过免疫组织化学染色检查从91例患者获取的浸润性乳腺癌组织中标准CD44抗原和变异CD44抗原(v5、v6、v7、v7 - v8和v8 - v10)的表达,以研究这些抗原与临床病理因素及预后的关系。在91例原发性人类乳腺癌患者中,54.9%检测到标准CD44抗原的表达。所检测的CD44变异表位,即v5、v6、v7、v7 - v8和v8 - v10,表达率分别为54.9%、54.9%、0%、34.1%和0%。外显子v7 - v8阳性患者与该变异体阴性患者在肿瘤大小、淋巴结状态和淋巴管浸润程度方面存在显著差异(p < 0.01)。CD44 v7 - v8阳性患者的预后也明显比该变异体阴性患者差。然而,对肿瘤大小、淋巴结状态和淋巴管浸润程度这三个预后指标进行多因素分析表明,乳腺癌中CD44 v7 - v8抗原的表达不是一个显著的独立预后因素,且与淋巴管浸润和淋巴结状态密切相关。31例CD44 v7 - v8阳性患者中有14例复发。这14例患者中有10例的复发模式为淋巴转移。表达v7 - v8 CD44抗原的乳腺癌细胞对淋巴结和淋巴管具有极高的亲和力,甚至在疾病进展的早期阶段就可能转移至远处淋巴结。这表明,乳腺癌淋巴结转移的发生不仅与解剖学因素有关,器官亲和力也起着重要作用。